Repligen Corp: completes mergers and BioLife delisted from Nasdaq

What happened Repligen reported that the mergers with BioLife closed and that, as a result of the mergers, BioLife has ceased to exist as a separate legal entity. The filing says BioLife notified Nasdaq that it anticipated closing prior to the opening of trading on Oct 6, 2026, requested trading be halted after the after-market session at or about 8:00 p.m., Eastern Time, on Oct 5, 2026, and on Oct 6, 2026 confirmed the mergers had closed. Repligen issued a press release on Oct 6, 2026 announcing the closing. The filing incorporates by reference the information set forth in the "Explanatory Note" of this Current Report on Form 8-K.

Key details

• BioLife notified Nasdaq it anticipated closing before the opening of trading on Oct 6, 2026, and requested a halt of trading following the after-market session at or about 8:00 p.m., Eastern Time, on Oct 5, 2026.
• BioLife requested Nasdaq, subject to confirmation of closing on Oct 6, 2026, to suspend trading as of the close of business on Oct 6, 2026, and to file Form 25 to delist and deregister BioLife Common Stock under Section 12(b) of the Exchange Act.
• On Oct 6, 2026, BioLife notified Nasdaq that the mergers had closed and Repligen issued a press release announcing the closing.
• Regarding financials, the filing states that Repligen intends to file financial statements of the business acquired, if required.

Why it may matter

• Item 2.01 (completion of acquisition or disposition of assets) was reported and covers the closing of the mergers described in the filing.
• Item 7.01 (Regulation FD disclosure) was reported and covers BioLife ceasing to exist as a separate legal entity and the related Nasdaq delisting and deregistration steps.
• Item 9.01 (financial statements and exhibits) was reported to note that Repligen intends to file financial statements of the business acquired if required. The filing does not show why the insider traded or why the company acted.